Parkman Healthcare Partners’s Vaxcyte PCVX Stock Holding History

Parkman Healthcare Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-93,431	Closed	-$3.53M	–	98
2025 Q1	$3.53M	Sell	93,431 -22,707	-20%	-$1.82M	0.42%	61
2024 Q4	$9.51M	Sell	116,138 -14,111	-11%	-$1.4M	1.27%	31
2024 Q3	$14.9M	Sell	130,249 -19,942	-13%	-$1.8M	1.9%	18
2024 Q2	$11.3M	Buy	150,191 +235	+0.2%	+$16K	1.52%	23
2024 Q1	$10.2M	Sell	149,956 -117,638	-44%	-$8.15M	1.26%	31
2023 Q4	$16.8M	Buy	267,594 +29,462	+12%	+$1.53M	2.37%	13
2023 Q3	$12.1M	Buy	238,132 +9,627	+4%	+$475K	2.22%	9
2023 Q2	$11.4M	Buy	228,505 +42,408	+23%	+$2.01M	1.98%	14
2023 Q1	$6.97M	Buy	186,097 +28,049	+18%	+$1.19M	1.52%	28
2022 Q4	$7.58M	Buy	+158,048	New	+$6.2M	2.02%	13

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Parkman Healthcare Partners's PCVX Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 93,431 shares — an estimated $3.53M sold.

Parkman Healthcare Partners first reported a position in PCVX in Q4 2022 and held it in 10 quarters. The position peaked at $16.8M in Q4 2023. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Parkman Healthcare Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 93,431 Vaxcyte shares in Q2 2025, an estimated $3.53M.
Parkman Healthcare Partners first reported a position in Vaxcyte in Q4 2022 and held it in 10 quarters.
Parkman Healthcare Partners's Vaxcyte position peaked at $16.8M in Q4 2023.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.